Zoetis wins EU approval for a dual poultry vaccine

Signals Inbox·July 7, 2026·Animal Health

Zoetis has won EU approval for a vaccine that protects chickens against Newcastle disease and Marek’s disease with one dose. The vaccine is not new. It was first approved in the US in 2019 and is already cleared in more than 35 markets. What changed is that Europe has opened the door just as Newcastle outbreaks are hitting several EU countries.

Q1What actually happened?

The European Commission granted marketing authorization for Zoetis’ Poulvac Procerta HVT-ND. It is a live recombinant vaccine that protects chickens against Newcastle disease and Marek’s disease with one dose. It can be given inside the egg before hatching or injected when the chick hatches.

Q2Why does one dose matter?

Commercial hatcheries handle thousands or even millions of birds, so every extra vaccine step adds labor, equipment, mistakes, and stress. A single dose against two serious diseases makes protection easier to fit into the hatchery workflow. It also starts protecting birds before they enter farms, where disease control becomes harder.

Q3Is this a completely new vaccine?

No. That is the important comparison. The US approved it in 2019, and it is already approved in more than 35 markets. Europe is joining a rollout that has been happening for years. The signal is less about a scientific breakthrough and more about Zoetis opening another large regulated market.

Q4Why is the European timing important?

Newcastle disease has recently appeared in Germany, Spain, and Poland. It spreads quickly, can kill large numbers of birds, and can force farms to destroy infected flocks. That turns this approval from a routine portfolio update into a timely new defense for European producers.

Q5Does Zoetis already sell a broader version?

Yes. Europe approved Poulvac Procerta HVT-IBD-ND in 2025. That version covers three diseases: Newcastle, Marek’s, and infectious bursal disease. The newly approved vaccine covers two. That sounds less powerful, but it gives producers a more targeted option when they do not need all three protections in one product.

Q6Why could an EU approval matter outside Europe?

Zoetis says it could help poultry producers in Southeast Asia export into markets that recognize vaccines approved by the EU. So the clearance is not only about selling doses to European farms. It could also make the vaccine more useful in global poultry trade and disease-control programs.

Q7So what is the real signal?

Zoetis is turning an established vaccine platform into a wider global franchise. The technology uses turkey herpesvirus as a carrier, an approach poultry companies have used for about two decades. The edge is not that the science appeared overnight. It is that one-dose protection is becoming available across more markets at a moment when outbreaks are making biosecurity more valuable.